[go: up one dir, main page]

UA91535C2 - IMIDAZO(1, 2-a)PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS - Google Patents

IMIDAZO(1, 2-a)PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS

Info

Publication number
UA91535C2
UA91535C2 UAA200709559A UAA200709559A UA91535C2 UA 91535 C2 UA91535 C2 UA 91535C2 UA A200709559 A UAA200709559 A UA A200709559A UA A200709559 A UAA200709559 A UA A200709559A UA 91535 C2 UA91535 C2 UA 91535C2
Authority
UA
Ukraine
Prior art keywords
vegf
inhibitors
imidazo
pyridine compounds
compounds
Prior art date
Application number
UAA200709559A
Other languages
English (en)
Ukrainian (uk)
Inventor
Дейвид Энтони Барда
Тимоти Пол Беркхолдер
Джошуа Райан Клейтон
Янь Хао
Перри К. Хит
Джеймз Роберт Хенри
Джон Монте Нобелок
Дейвид Мендел
Джонатан Александер Маклейн
Дейвид Майкл Ремик
Марк Эдвард Ремпала
Чжао-Цин Ван
Ивон Йи Мей Йип
Боюй Чжон
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of UA91535C2 publication Critical patent/UA91535C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Это изобретение предлагает соединения, которые являются ингибиторами VEGF-R2, формулы(И)и использование этих соединений.
UAA200709559A 2005-02-24 2006-02-23 IMIDAZO(1, 2-a)PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS UA91535C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65598105P 2005-02-24 2005-02-24

Publications (1)

Publication Number Publication Date
UA91535C2 true UA91535C2 (en) 2010-08-10

Family

ID=36587138

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200709559A UA91535C2 (en) 2005-02-24 2006-02-23 IMIDAZO(1, 2-a)PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS

Country Status (33)

Country Link
US (1) US7666879B2 (ru)
EP (1) EP1904494B1 (ru)
JP (1) JP5055136B2 (ru)
KR (1) KR100904938B1 (ru)
CN (1) CN101128461B (ru)
AR (1) AR056186A1 (ru)
AT (1) ATE490254T1 (ru)
AU (1) AU2006216710B2 (ru)
BR (1) BRPI0609047A2 (ru)
CA (1) CA2599124C (ru)
CR (1) CR9331A (ru)
CY (1) CY1111154T1 (ru)
DE (1) DE602006018615D1 (ru)
DK (1) DK1904494T3 (ru)
DO (1) DOP2006000051A (ru)
EA (1) EA011691B1 (ru)
ES (1) ES2354716T3 (ru)
HR (1) HRP20100677T1 (ru)
IL (1) IL184717A (ru)
MA (1) MA29433B1 (ru)
MX (1) MX2007010326A (ru)
NO (1) NO20074666L (ru)
NZ (2) NZ584753A (ru)
PE (1) PE20061098A1 (ru)
PL (1) PL1904494T3 (ru)
PT (1) PT1904494E (ru)
RS (1) RS51590B (ru)
SI (1) SI1904494T1 (ru)
TN (1) TNSN07323A1 (ru)
TW (1) TW200640924A (ru)
UA (1) UA91535C2 (ru)
WO (1) WO2006091671A1 (ru)
ZA (1) ZA200707136B (ru)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101679408B (zh) 2006-12-22 2016-04-27 Astex治疗学有限公司 作为fgfr抑制剂的双环杂环化合物
US8513276B2 (en) 2006-12-22 2013-08-20 Astex Therapeutics Limited Imidazo[1,2-a]pyridine compounds for use in treating cancer
US8131527B1 (en) 2006-12-22 2012-03-06 Astex Therapeutics Ltd. FGFR pharmacophore compounds
WO2008112164A2 (en) 2007-03-08 2008-09-18 The Board Of Trustees Of The Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
GB0720041D0 (en) * 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
CN101827844B (zh) * 2007-10-17 2013-08-14 诺瓦提斯公司 可用作ALK抑制剂的咪唑并[1,2-a]吡啶衍生物
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
EP2337563B1 (en) 2008-09-08 2014-04-09 The Board of Trustees of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
WO2010062308A1 (en) 2008-10-28 2010-06-03 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase and methods of use thereof
JO3265B1 (ar) 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
TW201124391A (en) 2009-10-20 2011-07-16 Lundbeck & Co As H 2-substituted-ethynylthiazole derivatives and uses of same
GB201009731D0 (en) 2010-06-10 2010-07-21 Pulmagen Therapeutics Inflamma Kinase inhibitors
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
WO2012149106A1 (en) 2011-04-29 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
AR090566A1 (es) * 2012-04-02 2014-11-19 Boehringer Ingelheim Int Proceso para la produccion de inhibidores de crr
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
JP6430383B2 (ja) * 2012-09-28 2018-11-28 ヴァンダービルト ユニバーシティーＶａｎｄｅｒｂｉｌｔ Ｕｎｉｖｅｒｓｉｔｙ 選択的ｂｍｐ阻害剤としての縮合複素環化合物
JP6007339B2 (ja) * 2012-11-29 2016-10-12 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ イミダゾピリジン誘導体
CN105358531B (zh) 2013-03-14 2017-11-14 利兰-斯坦福大学初级学院的董事会 线粒体醛脱氢酶‑2调节剂和其使用方法
KR20220112867A (ko) 2013-12-16 2022-08-11 에이비에스 디벨롭먼트 원 인코포레이티드 P2x3 및/또는 p2x2/3 화합물 및 방법
CN103772308B (zh) * 2013-12-31 2015-11-18 北京颖泰嘉和生物科技股份有限公司 5-氨基-3-(1-乙基-1-甲基丙基)异噁唑中间体的制备方法和异噁草胺的制备方法
US9988371B2 (en) 2014-06-03 2018-06-05 The Arizona Board Of Regents On Behalf Of The University Of Arizona Benzimidazole analogues and related methods
US10065934B2 (en) 2014-07-17 2018-09-04 Sunshine Lake Pharma Co., Ltd. Substituted urea derivatives and pharmaceutical uses thereof
CN104163790B (zh) * 2014-08-19 2016-02-10 贵州威顿晶磷电子材料股份有限公司 一种2-氨基-4-甲基-5溴吡啶的制备工艺
WO2017019804A2 (en) 2015-07-28 2017-02-02 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CA2997556C (en) 2015-09-03 2020-12-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of dyrk1a and uses thereof
ES2904615T3 (es) * 2016-03-16 2022-04-05 Plexxikon Inc Compuestos y métodos para la modulación de quinasas e indicaciones al respecto
US12528810B2 (en) 2018-03-01 2026-01-20 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of DYRK/CLK and uses thereof
WO2019178383A1 (en) 2018-03-14 2019-09-19 Vanderbilt University Inhibition of bmp signaling, compounds, compositions and uses thereof
US10239885B1 (en) 2018-06-18 2019-03-26 Avista Pharma Solutions, Inc. Compound 1-[2-[4-(2-ethyl-6,8-dimethylimidazo[1,2-α]pyrazin-3-yl)phenyl]ethyl]-3-(p-tolylsulfonyl)urea as a prostaglandin EP4 receptor antagonist
TW202043205A (zh) 2018-12-31 2020-12-01 美商拜歐米富士恩有限公司 Menin-mll相互作用之抑制劑
WO2020142557A1 (en) 2018-12-31 2020-07-09 Biomea Fusion, Llc Irreversible inhibitors of menin-mll interaction
PE20211733A1 (es) 2019-01-11 2021-09-06 Gruenenthal Chemie Amidas de pirrolidina sustituidas
CA3128346A1 (en) 2019-01-30 2020-08-06 Avista Pharma Solutions, Inc. Synthetic process and novel intermediates
US11459331B2 (en) 2019-01-30 2022-10-04 Avista Pharma Solutions, Inc. Chemical compounds
JP7323218B2 (ja) * 2019-02-18 2023-08-08 深▲チェン▼市塔吉瑞生物医薬有限公司 置換された縮合芳香環誘導体、その組成物、およびそれらの使用
CN114450285B (zh) * 2019-06-25 2024-04-09 西诺普塞疗法公司 用于治疗眼部病症的化合物
CN112778294A (zh) * 2021-01-07 2021-05-11 苏州安睿药业有限公司 5-氨基异噁唑衍生物及其在制备多激酶抑制剂中的应用
EP4384179A1 (en) 2021-08-11 2024-06-19 Biomea Fusion, Inc. Covalent inhibitors of menin-mll interaction for diabetes mellitus
CN119816500A (zh) 2021-08-20 2025-04-11 拜欧米富士恩公司 用于治疗癌症的不可逆menin-MLL抑制剂N-[4-[4-(4-吗啉基)-7H-吡咯并[2,3-d]嘧啶-6-基]苯基]-4-[[3(R)-[(1-氧代-2-丙烯-1-基)氨基]-1-哌啶基]甲基]-2-吡啶甲酰胺的结晶形式
WO2024155710A1 (en) 2023-01-18 2024-07-25 Biomea Fusion, Inc. Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6- yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2-pyridinecarboxamide as a covalent inhibitor of menin-mll interaction
WO2025038525A1 (en) * 2023-08-11 2025-02-20 Bioventures, Llc Fms-like tyrosine kinase 3 (flt3) inhibitors for treating cell proliferative diseases or conditions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69734149T2 (de) 1996-03-15 2006-07-06 Astrazeneca Ab Cinoline derivate und verwendung als heilmittel
EP1017682A4 (en) 1997-09-26 2000-11-08 Merck & Co Inc NEW ANGIOGENESIS INHIBITORS
WO2001004115A2 (en) 1999-07-09 2001-01-18 Boehringer Ingelheim Pharmaceuticals, Inc. Novel process for synthesis of heteroaryl-substituted urea compounds
US6492529B1 (en) * 2000-01-18 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Bis pyrazole-1H-pyrazole intermediates and their synthesis
ATE360417T1 (de) 2001-07-11 2007-05-15 Boehringer Ingelheim Pharma Methode zur behandlung von zytokinvermittelten erkrankungen
JP2003313126A (ja) * 2002-04-23 2003-11-06 Sankyo Co Ltd イミダゾピリジン誘導体を有効成分とする医薬
DE60318198T2 (de) * 2002-05-02 2008-12-04 Merck & Co., Inc. Tyrosinkinase-hemmer
US7550470B2 (en) * 2002-12-11 2009-06-23 Merck & Co. Inc. Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors
AU2003298942A1 (en) * 2002-12-11 2004-06-30 Merck And Co., Inc. Tyrosine kinase inhibitors
WO2005016928A1 (ja) 2003-08-15 2005-02-24 Banyu Pharmaceutical Co., Ltd. イミダゾピリジン誘導体

Also Published As

Publication number Publication date
AR056186A1 (es) 2007-09-26
CN101128461B (zh) 2010-12-22
NZ560402A (en) 2010-06-25
TNSN07323A1 (en) 2008-12-31
EP1904494A1 (en) 2008-04-02
DOP2006000051A (es) 2006-08-31
CN101128461A (zh) 2008-02-20
AU2006216710A1 (en) 2006-08-31
CR9331A (es) 2008-03-31
KR100904938B1 (ko) 2009-06-29
NO20074666L (no) 2007-11-09
EA200701802A1 (ru) 2008-02-28
PT1904494E (pt) 2010-12-23
NZ584753A (en) 2011-06-30
EA011691B1 (ru) 2009-04-28
MA29433B1 (fr) 2008-05-02
MX2007010326A (es) 2007-10-16
PE20061098A1 (es) 2006-10-20
ES2354716T3 (es) 2011-03-17
HK1118284A1 (en) 2009-02-06
CA2599124A1 (en) 2006-08-31
IL184717A (en) 2011-11-30
IL184717A0 (en) 2007-12-03
ATE490254T1 (de) 2010-12-15
DK1904494T3 (da) 2011-02-21
AU2006216710B2 (en) 2011-08-11
KR20070099029A (ko) 2007-10-08
SI1904494T1 (sl) 2011-02-28
US20090227622A1 (en) 2009-09-10
RS51590B (sr) 2011-08-31
HRP20100677T1 (hr) 2011-01-31
JP5055136B2 (ja) 2012-10-24
WO2006091671A1 (en) 2006-08-31
TW200640924A (en) 2006-12-01
BRPI0609047A2 (pt) 2010-11-16
ZA200707136B (en) 2008-11-26
JP2008531574A (ja) 2008-08-14
US7666879B2 (en) 2010-02-23
PL1904494T3 (pl) 2011-04-29
CA2599124C (en) 2013-08-06
CY1111154T1 (el) 2015-06-11
DE602006018615D1 (de) 2011-01-13
EP1904494B1 (en) 2010-12-01

Similar Documents

Publication Publication Date Title
TNSN07323A1 (en) Imidazo (1, 2-a) pyridine compounds as vegf-r2 inhibitors
MXPA05012025A (es) Imidazo y tiazolopiridinas como inhibidores de cinasa jak3.
TW200510407A (en) Novel pyrrolodihydroisoquinolines as PDE 10 inhibitors
JO3181B1 (ar) مشتقات كمحول ثاني الكيل البايردينيل - أحادي الفينيل كأنزيم ثنائي استرات الفوسفود
IL160915A0 (en) Indolizines inhibiting kinase proteins
MXPA05012026A (es) Compuestos de azaindol como inhibidores de cinasa.
ZA200701137B (en) Triazolophthalazines
MX2007008137A (es) Triazoloftalazinas como inhibidores de pde2.
PL1761520T3 (pl) Inhibitory kinazy
TW200728277A (en) Bicyclic derivatives as P38 inhibitors
UA83875C2 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
TW200624426A (en) BACE inhibitors
WO2007097981A3 (en) Alpha carbolines and uses thereof
MX2009006885A (es) Derivados de pirrolo[3,2-a]piridina para inhibir la actividad de la proteina cinesina del huso.
WO2006034113A3 (en) Quinolone analogs as cell proliferation inhibitors
WO2010021934A3 (en) Azaindole inhibitors of iap
TNSN07440A1 (en) Derivatives of pyrido [2,3 -d] pyrimidine, the preparation thereof, and the therapeutic application of the same
MX2008001538A (es) Aril piridinas y metodos para su uso.
WO2006072612A3 (en) Triazolophthalazines as pde2- inhibitors
TW200700064A (en) Novel compounds
UA88638C2 (ru) Бета-карболины, полезные для лечения воспалительного заболевания
UA85505C2 (en) Kinase inhibitors
WO2007120333A3 (en) Tetracyclic kinase inhibitors
DK1742950T3 (da) Pyrazolo-[4,3-D]-pyrimidiner
TW200602326A (en) Tricyclic imidazopyridines